+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Immunohistochemical detection of P-glycoprotein in endometrial adenocarcinoma



Immunohistochemical detection of P-glycoprotein in endometrial adenocarcinoma



American Journal of Pathology 138(4): 799-806



P-glycoprotein (Pgp) has emerged as the central mediator in classic multidrug resistance in model systems in vitro. High levels of Pgp also have been detected in many normal human tissues and tumors; and its role in clinical drug resistance is currently under investigation. Recently significant levels of Pgp were localized to gravid and secretory endometrium; and it was demonstrated that the combination of estrogen and progesterone is sufficient to induce high levels of both Pgp mRNA and Pgp in uterine secretory epithelium. These findings suggest that increased Pgp expression also may be present in hormone-responsive malignancies such as endometrial adenocarcinoma. To determine whether Pgp is expressed in endometrial adenocarcinoma, 36 endometrial adenocarcinomas (grade I [n = 17]; grade II [n = 6]; grade III [n = 13]) were investigated retrospectively by the avidin-biotin-complex immunohistochemical procedure using three murine monoclonal antibodies (MAb) MAb C219, MAb C494, and MAb JSB-1, which recognize spatially distinct cytoplasmic epitopes of Pgp. Seventy-two percent of the tumors showed positive immunostaining with at least one MAb; 67% showed immunostaining with MAb C219, 50% with MAb C494, and 62% with MAb JSB-1. Forty-six percent of tumors were immunoreactive to two and 29% to all three antibodies. Membranous and Golgi/paranuclear type staining patterns were observed. Overall the intensity of immunostaining varied from one sample to another for a given tumor type, and considerable heterogeneity of expression was commonly seen within a given tumor. Strong to moderate immunoreactivity was seen in diffusely infiltrating, adenosquamous, and serous papillary carcinomas. In general, immunoreactivity to MAb C494 was weaker than MAb C219 or MAb JSB-1. Adenomatous and non-neoplastic endometrium adjacent to the tumors displayed strong membranous immunostaining with MAb JSB-1. Endometrial capillaries showed weak-to-moderate immunostaining to all three antibodies. It is concluded that Pgp is commonly expressed in endometrial adenocarcinoma and may be a significant factor responsible for their drug-resistant nature subject to modulation by progesterone.

(PDF emailed within 1 workday: $29.90)

Accession: 040362459

Download citation: RISBibTeXText

PMID: 1707232


Related references

Immunohistochemical detection of human telomerase reverse transcriptase (hTERT), topoisomerase IIalpha expression, and apoptosis in endometrial adenocarcinoma and atypical hyperplasia. International Journal of Gynecological Pathology 24(2): 184-192, 2005

Predicting the coexistence of an endometrial adenocarcinoma in the presence of atypical complex hyperplasia: immunohistochemical analysis of endometrial samples. International Journal of Gynecological Cancer 22(7): 1264-1272, 2013

Immunohistochemical evaluation of PTEN protein in patients with endometrial intraepithelial neoplasia compared to endometrial adenocarcinoma and proliferative phase endometrium. European Journal of Gynaecological Oncology 27(4): 389-392, 2006

The detection of proliferative activity by PCNA and Ki-67 in endometrial hyperplasia and endometrial adenocarcinoma. Pathology Research & Practice 193(5-6): 441, 1997

An immunohistochemical study of feline endometrial adenocarcinoma. Journal of Comparative Pathology 140(4): 254-259, 2009

Immunohistochemical properties of the endometrial and cervical adenocarcinoma. Nihon Sanka Fujinka Gakkai Zasshi 38(12): 2287-2288, 1986

Distinction between endometrial and endocervical adenocarcinoma: an immunohistochemical study. International Journal of Gynecological Pathology 21(1): 4-10, 2002

Immunohistochemical investigation of vimentin of uterine endometrial and endocervical adenocarcinoma. Nihon Sanka Fujinka Gakkai Zasshi 42(9): 1237-1243, 1990

Histopathologic and immunohistochemical exam in one case of canine endometrial adenocarcinoma. Reproduction in Domestic Animals 45(3): 545-549, 2010

Immunohistochemical demonstration of carcinoembryonic antigen and ultrastructural features of endometrial adenocarcinoma. Nihon Sanka Fujinka Gakkai Zasshi 36(2): 173-181, 1984

The utilization of immunohistochemical prognostic factor in endometrial adenocarcinoma: is it cost effective?. European Journal of Gynaecological Oncology 21(2): 197-199, 2000

Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Research 46(10): 5419-5425, 1986

Immunohistochemical profile of endometrial adenocarcinoma: A study of 61 cases and review of the literature. Modern Pathology 13(4): 379-388, 2000

Reverse correlation between P-glycoprotein expression and proliferative activity in endometrial adenocarcinoma. European Journal of Obstetrics & Gynecology & Reproductive Biology 59(1): 45-51, 1995

Role of tumor-associated glycoprotein-72 in the progression of endometrial adenocarcinoma: a proposed study. Medical Hypotheses 84(5): 413-416, 2015